Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells

S Fulda, I Jeremias, KM Debatin - Oncogene, 2004 - nature.com
S Fulda, I Jeremias, KM Debatin
Oncogene, 2004nature.com
We previously reported that the TRAIL (tumor necrosis factor (TNF)-related apoptosis-
inducing ligand)-induced death signal requires amplification by mitochondria in certain cell
types, for example, in type II cells. Here, we provide for the first time evidence that the natural
compound betulinic acid (BetA) cooperated with TRAIL to induce apoptosis in tumor cells.
Through functional complementation, simultaneous stimulation of the death receptor
pathway by TRAIL and the mitochondrial pathway by BetA resulted in complete activation of …
Abstract
We previously reported that the TRAIL (tumor necrosis factor (TNF)-related apoptosis-inducing ligand)-induced death signal requires amplification by mitochondria in certain cell types, for example, in type II cells. Here, we provide for the first time evidence that the natural compound betulinic acid (BetA) cooperated with TRAIL to induce apoptosis in tumor cells. Through functional complementation, simultaneous stimulation of the death receptor pathway by TRAIL and the mitochondrial pathway by BetA resulted in complete activation of effector caspases, apoptosis and inhibition of clonogenic survival. BetA and TRAIL cooperated to trigger loss of mitochondrial membrane potential and release of cytochrome c and Smac from mitochondria. Also, combination treatment with BetA and TRAIL resulted in increased cleavage of caspase-8 and Bid indicating that activation of effector caspases may feed back in a positive amplification loop. Importantly, the combination treatment with BetA and TRAIL cooperated to induce apoptosis in different tumor cell lines and also in primary tumor cells, but not in normal human fibroblasts indicating some tumor specificity. Since most human cancers represent type II cells, triggering the mitochondrial pathway by BetA may be a novel approach to enhance the efficacy of TRAIL-based therapies, which warrants further investigation.
nature.com